StockSignal
  • Screen for fundamentally interesting stocks
Sign in
Guangxi Liyao Group Co. Ltd. logo

Guangxi Liyao Group Co. Ltd.

603368 · XSHG · Medical Distribution · China

Market Capitalization6.90B CNY
Trailing P/E8.82 CNY
52-Week Change-8.28 CNY
Forward Annual Dividend Yield17.50%
Beta0.4430 CNY

Guangxi Liyao Group Co. Ltd. is a prominent company involved in the construction materials industry, primarily focusing on the production and supply of ceramics. Known for its specialization in ceramic tiles, the company plays a crucial role in meeting the demand for aesthetic and durable building materials in residential, commercial, and industrial sectors. Guangxi Liyao Group Co. Ltd. delivers a wide variety of ceramic products that meet international standards, emphasizing quality, innovation, and sustainability in its manufacturing processes. By leveraging advanced technologies and adhering to rigorous quality controls, the company supports infrastructure development and architectural projects. Serving both domestic and international markets, Guangxi Liyao Group Co. Ltd. is instrumental in enhancing the supply chain dynamics in the construction materials domain, while also contributing to the economic growth in regions where it operates. Its strategic market presence and dedicated customer-oriented services enable it to maintain a significant position among its peers in the ceramics manufacturing sector.

Industry

Medical Distribution

Healthcare sector · China

Stories

Structural patterns identified in Guangxi Liyao Group Co. Ltd.

No stories identified yet.

Key Metrics

Market Capitalization
6.90BCNY
NormalMar 19, 2026
Trailing P/E
8.82CNY
NormalMar 19, 2026
Revenue (TTM)
20.95BCNY
NormalMar 19, 2026
Profit Margin
3.75%
NormalMar 19, 2026
Beta
0.4430CNY
NormalMar 19, 2026
52-Week Change
-8.28CNY
ExtremeMar 19, 2026
Forward Annual Dividend Yield
17.50%
AboveNormalMar 19, 2026
Forward Yield
17.50%
Above 5Y avg (3.17%)
Annual Rate
CNY 3.00
Paid annual
Payout Ratio
38.1%
Sustainable
Loading dividend history...

Track Record

Frequency
Annual
Payback Period
22.9 yr
Years to recoup investment via dividends alone

Upcoming

Ex-Dividend Date
May 29, 2025

Screen for dividend patterns

Find other stocks with similar dividend characteristics in the screener.

Dividend Fortress
→
dividend consistency
dividend quality
free cash flow conversion
Open in Screener
Dividend Growth Track
→
dividend growth rate
dividend streak
dividend consistency
Open in Screener
Dividend Sustainability
→
dividend quality
common dividends to free cash flow
dividend stress
Open in Screener
Valuation9
Market Capitalization
6.90BCNY
NormalMar 19, 2026
Enterprise Value
9.02BCNY
NormalMar 19, 2026
Trailing P/E
8.82CNY
NormalMar 19, 2026
Forward P/E
6.66CNY
NormalMar 19, 2026
PEG Ratio
6.66CNY
AboveNormalMar 19, 2026
Price to Sales (TTM)
0.3296CNY
NormalMar 19, 2026
Price to Book (MRQ)
0.8642CNY
NormalMar 19, 2026
Enterprise to Revenue
0.4300CNY
NormalMar 19, 2026
Enterprise to EBITDA
7.42CNY
NormalMar 19, 2026
Profitability & Growth42
Gross Margin
10.06%
NormalMar 19, 2026
Profit Margin
3.75%
NormalMar 19, 2026
Operating Margin
5.65%
NormalMar 19, 2026
Return on Assets (TTM)
0.0320CNY
NormalMar 19, 2026
Return on Equity (TTM)
0.0946CNY
NormalMar 19, 2026
Revenue (TTM)
20.95BCNY
NormalMar 19, 2026
Revenue per Share (TTM)
52.79CNY
NormalMar 19, 2026
Quarterly Revenue Growth
0.0200CNY
NormalMar 19, 2026
Gross Profit (TTM)
2.22BCNY
NormalMar 19, 2026
EBITDA
1.28BCNY
ExtremeMar 19, 2026
Net Income (TTM)
784.68MCNY
NormalMar 19, 2026
Quarterly Earnings Growth (YoY)
-0.1400CNY
NormalMar 19, 2026
Operating Cash Flow (TTM)
850.92MCNY
NormalMar 19, 2026
Levered Free Cash Flow (TTM)
481.14MCNY
NormalMar 19, 2026
Forward Annual Dividend Rate
3.00CNY
NormalMar 19, 2026
Forward Annual Dividend Yield
17.50%
AboveNormalMar 19, 2026
Trailing Annual Dividend Rate
0.7510CNY
NormalMar 19, 2026
Trailing Annual Dividend Yield
4.37%
NormalMar 19, 2026
5-Year Average Dividend Yield
317.00%
ExtremeMar 19, 2026
Payout Ratio
0.3812CNY
NormalMar 19, 2026
Minority Interest (Equity)
312.51M
NormalFY2024 · Dec 31, 2024
Revenue
21.18B
NormalFY2024 · Dec 31, 2024
Cost of Goods Sold
18.77B
NormalFY2024 · Dec 31, 2024
Gross Profit
2.41B
NormalFY2024 · Dec 31, 2024
Operating Income
1.27B
NormalFY2024 · Dec 31, 2024
Pre-tax Income
1.00B
NormalFY2024 · Dec 31, 2024
Income Tax Expense
135.60M
NormalFY2024 · Dec 31, 2024
Net Income
867.53M
NormalFY2024 · Dec 31, 2024
EBIT
1.04B
NormalFY2024 · Dec 31, 2024
ebitda-income
1.28B
NormalFY2024 · Dec 31, 2024
Research & Development
39.63M
NormalFY2024 · Dec 31, 2024
Selling, General & Administrative
495.06M
NormalFY2024 · Dec 31, 2024
Other Operating Expenses
90.41M
NormalFY2024 · Dec 31, 2024
Non-operating Interest Income
36.93M
NormalFY2024 · Dec 31, 2024
Non-operating Interest Expense
40.86M
NormalFY2024 · Dec 31, 2024
EPS (Basic)
2.21
NormalFY2024 · Dec 31, 2024
EPS (Diluted)
2.21
NormalFY2024 · Dec 31, 2024
Basic Shares Outstanding
386.82MShares
NormalFY2024 · Dec 31, 2024
Diluted Shares Outstanding
386.82MShares
NormalFY2024 · Dec 31, 2024
Net Income from Continuing Operations
867.53M
NormalFY2024 · Dec 31, 2024
Minority Interests (P&L)
-12.66M
NormalFY2024 · Dec 31, 2024
Preferred Stock Dividends
0.00
NormalFY2024 · Dec 31, 2024
Financial Strength30
Shares Outstanding
398.86MShares
NormalMar 19, 2026
Float Shares
279.62MCNY
NormalMar 19, 2026
% Held by Insiders
0.3366CNY
NormalMar 19, 2026
% Held by Institutions
0.0291CNY
NormalMar 19, 2026
Total Cash (MRQ)
2.69BCNY
NormalMar 19, 2026
Total Cash per Share (MRQ)
6.92CNY
NormalMar 19, 2026
Total Debt (MRQ)
4.64BCNY
NormalMar 19, 2026
Total Debt to Equity (MRQ)
57.07CNY
ExtremeMar 19, 2026
Current Ratio (MRQ)
1.64CNY
NormalMar 19, 2026
Book Value per Share (MRQ)
20.11CNY
NormalMar 19, 2026
Total Assets
21.27B
NormalFY2024 · Dec 31, 2024
Total Current Assets
18.61B
NormalFY2024 · Dec 31, 2024
Total Liabilities
13.33B
NormalFY2024 · Dec 31, 2024
Total Non-current Assets
2.66B
NormalFY2024 · Dec 31, 2024
Total Non-current Liabilities
1.47B
NormalFY2024 · Dec 31, 2024
Total Current Liabilities
11.86B
NormalFY2024 · Dec 31, 2024
Cash
3.43B
NormalFY2024 · Dec 31, 2024
Cash Equivalents
258.25M
NormalFY2024 · Dec 31, 2024
Cash & Cash Equivalents
3.68B
NormalFY2024 · Dec 31, 2024
Accounts Receivable
10.60B
NormalFY2024 · Dec 31, 2024
Inventory
2.64B
NormalFY2024 · Dec 31, 2024
Accounts Payable
6.92B
NormalFY2024 · Dec 31, 2024
Short-term Debt
3.07B
NormalFY2024 · Dec 31, 2024
Other Current Liabilities
340.00M
NormalFY2024 · Dec 31, 2024
Long-term Debt
1.13B
NormalFY2024 · Dec 31, 2024
Other Non-current Liabilities
235.71M
NormalFY2024 · Dec 31, 2024
Common Stock (Book)
399.03M
NormalFY2024 · Dec 31, 2024
Retained Earnings
4.52B
NormalFY2024 · Dec 31, 2024
Total Shareholders' Equity
7.94B
NormalFY2024 · Dec 31, 2024
Treasury Stock
18.99M
ExtremeFY2024 · Dec 31, 2024
Market & Technical9
52-Week Low
15.92CNY
NormalMar 19, 2026
52-Week High
20.92CNY
NormalMar 19, 2026
52-Week Change
-8.28CNY
ExtremeMar 19, 2026
Beta
0.4430CNY
NormalMar 19, 2026
50-Day MA
18.01CNY
NormalMar 19, 2026
200-Day MA
18.15CNY
NormalMar 19, 2026
Avg 10-Day Volume
3.89MCNY
NormalMar 19, 2026
Avg 30-Day Volume
4.67MCNY
NormalMar 19, 2026
Diluted EPS (TTM)
1.97CNY
NormalMar 19, 2026

Coordination

Placeholder CorpCoordination
Example HoldingsCoordination
Sample IncCoordination

Supply Chain

Blood Supply Chain

The blood supply chain is shaped by three root constraints: biological perishability that gives red blood cells a 42-day shelf life and platelets just 5 days — making stockpiling impossible, voluntary donor dependency that means the raw material cannot be manufactured and fluctuates with seasons and public events, and a type-matching requirement that forces individual testing of every unit — creating a processing bottleneck between collection and availability.

StockSignal
  • Blog
  • Industries
  • Glossary
  • Stories
  • Coordinations
  • Constraint Archetypes
  • Legal

Contact

© 2026 StockSignal. All rights reserved.